Loomis, Sayles & Company
GEVA

Loomis, Sayles & Company’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Loomis, Sayles & Company’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-113,189
Closed -$11.9M – 774
2014
Q2 		$11.9M Buy
113,189
+24,831
+28% +$2.11M 0.03% 478
2014
Q1 		$7.33M Buy
+88,358
New +$8.17M 0.02% 520

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Loomis, Sayles & Company's GEVA Position: Q3 2014 in Review

Loomis, Sayles & Company sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q3 2014, closing a stake of 113,189 shares — an estimated $11.9M sold.

Loomis, Sayles & Company first reported a position in GEVA in Q1 2014 and held it in 2 quarters. The position peaked at $11.9M in Q2 2014. 120 funds tracked by Wall St. Rank hold GEVA as of Q3 2014.

  • Loomis, Sayles & Company reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q3 2014 after selling out during the quarter.
  • Loomis, Sayles & Company sold 113,189 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q3 2014, an estimated $11.9M.
  • Loomis, Sayles & Company first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and held it in 2 quarters.
  • Loomis, Sayles & Company's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $11.9M in Q2 2014.
  • 120 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q3 2014.

Based on Loomis, Sayles & Company's 13F filing for Q3 2014, filed 14 Nov 2014.